Abstract
Understanding the function of individual microRNA (miRNA) species in mice would require the production of hundreds of loss-of-function strains. To accelerate analysis of miRNA biology in mammals, we combined recombinant adeno-associated virus (rAAV) vectors with miRNA 'tough decoys' (TuDs) to inhibit specific miRNAs. Intravenous injection of rAAV9 expressing anti–miR-122 or anti–let-7 TuDs depleted the corresponding miRNA and increased its mRNA targets. rAAV producing anti–miR-122 TuD but not anti–let-7 TuD reduced serum cholesterol by >30% for 25 weeks in wild-type mice. High-throughput sequencing of liver miRNAs from the treated mice confirmed that the targeted miRNAs were depleted and revealed that TuDs induced miRNA tailing and trimming in vivo. rAAV-mediated miRNA inhibition thus provides a simple way to study miRNA function in adult mammals and a potential therapy for dyslipidemia and other diseases caused by miRNA deregulation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Lewis, B.P., Burge, C.B. & Bartel, D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120, 15–20 (2005).
Lewis, B.P., Shih, I.H., Jones-Rhoades, M.W., Bartel, D.P. & Burge, C.B. Prediction of mammalian microRNA targets. Cell 115, 787–798 (2003).
Hutvagner, G., Simard, M.J., Mello, C.C. & Zamore, P.D. Sequence-specific inhibition of small RNA function. PLoS Biol. 2, E98 (2004).
Meister, G., Landthaler, M., Dorsett, Y. & Tuschl, T. Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 10, 544–550 (2004).
Krutzfeldt, J. et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685–689 (2005).
Elmen, J. et al. LNA-mediated microRNA silencing in non-human primates. Nature 452, 896–899 (2008).
Lanford, R.E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198–201 (2010).
Esau, C. et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3, 87–98 (2006).
Ebert, M.S., Neilson, J.R. & Sharp, P.A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4, 721–726 (2007).
Loya, C.M., Lu, C.S., Van Vactor, D. & Fulga, T.A. Transgenic microRNA inhibition with spatiotemporal specificity in intact organisms. Nat. Methods 6, 897–903 (2009).
Gentner, B. et al. Stable knockdown of microRNA in vivo by lentiviral vectors. Nat. Methods 6, 63–66 (2009).
Luikart, B.W. et al. miR-132 mediates the integration of newborn neurons into the adult dentate gyrus. PLoS ONE 6, e19077 (2011).
Berns, K.I. & Giraud, C. Biology of adeno-associated virus. Curr. Top. Microbiol. Immunol. 218, 1–23 (1996).
Gao, G.P. et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA 99, 11854–11859 (2002).
Krol, J. et al. Characterizing light-regulated retinal microRNAs reveals rapid turnover as a common property of neuronal microRNAs. Cell 141, 618–631 (2010).
Zhu, Q. et al. Sponge transgenic mouse model reveals important roles for the microRNA-183 (miR-183)/96/182 cluster in postmitotic photoreceptors of the retina. J. Biol. Chem. 286, 31749–31760 (2011).
Haraguchi, T., Ozaki, Y. & Iba, H. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res. 37, e43 (2009).
Rayner, K.J. et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 328, 1570–1573 (2010).
Ameres, S.L. et al. Target RNA-directed trimming and tailing of small silencing RNAs. Science 328, 1534–1539 (2010).
Chang, J. et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol. 1, 106–113 (2004).
Tannous, B.A. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat. Protoc. 4, 582–591 (2009).
Sen, C.K., Gordillo, G.M., Khanna, S. & Roy, S. Micromanaging vascular biology: tiny microRNAs play big band. J. Vasc. Res. 46, 527–540 (2009).
McCarty, D.M. Self-complementary AAV vectors; advances and applications. Mol. Ther. 16, 1648–1656 (2008).
Grimson, A. et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 27, 91–105 (2007).
Kutay, H. et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell. Biochem. 99, 671–678 (2006).
Coulouarn, C., Factor, V.M., Andersen, J.B., Durkin, M.E. & Thorgeirsson, S.S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28, 3526–3536 (2009).
Tsai, W.C. et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49, 1571–1582 (2009).
Griffiths-Jones, S., Grocock, R.J., van Dongen, S., Bateman, A. & Enright, A.J. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34, D140–D144 (2006).
Gao, G. et al. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl. Acad. Sci. USA 100, 6081–6086 (2003).
Nakabayashi, H., Taketa, K., Miyano, K., Yamane, T. & Sato, J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 42, 3858–3863 (1982).
Gao, G. et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol. Ther. 13, 77–87 (2006).
Acknowledgements
This work was supported in part by a European Molecular Biology Organization long-term fellowship (ALTF 522-2008) and an Erwin Schrödinger-Auslandsstipendium (Austrian Science Fund FWF, J2832-B09) to S.L.A. and by grants from the US National Institutes of Health to P.D.Z. (GM62862 and GM65236), to P.D.Z. and G.G. (UL1RR031982), to the University of Massachusetts Mouse Metabolic Phenotypic Center (U24-DK093000), and to T.R.F. (P01 DK58327), and from the University of Massachusetts Medical School to G.G.; T.R.F., J.K., P.D.Z., and G.G. are members of the University of Massachusetts Diabetes and Endocrinology Research Core, which is supported by a grant from the US National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK32520).
Author information
Authors and Affiliations
Contributions
J.X. created the miRNA inhibitor constructs, performed the experiments in cultured cells and mice. J.-H.H., S.L.A. and Z.W. analyzed high-throughput sequencing data. S.L.A. designed, conducted and analyzed the experiments to study how TuDs inhibit miRNAs. R.F. and J.K.K. measured cholesterol profiles and liver function in mice. Y.Z. contributed to most of the anti-miRNA TuD studies in mice. R.H. and Q.X. contributed to vector construction as well as in vitro characterization of miRNA inhibitors. L.Z., M.L., H.L. and X.M. contributed to the miRNA inhibitor studies in mice and tissue sample analyses. Q.S. and R.H. produced the AAV vectors. H.Z. assisted in in vitro characterization. J.A.B. designed and cloned anti-miRNA sponges. T.R.F. contributed to the development of rAAV delivered miRNA therapeutics for treating hyperlipidemia. J.X., S.L.A., P.D.Z. and G.G. conceived the research. S.L.A., J.X., P.D.Z. and G.G. wrote the manuscript. S.L.A. and P.D.Z. prepared the figures.
Corresponding authors
Ethics declarations
Competing interests
P.D.Z. is a member of the scientific advisory board of Regulus Therapeutics.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–9, Supplementary Tables 1–3 and Supplementary Note 1 (PDF 783 kb)
Rights and permissions
About this article
Cite this article
Xie, J., Ameres, S., Friedline, R. et al. Long-term, efficient inhibition of microRNA function in mice using rAAV vectors. Nat Methods 9, 403–409 (2012). https://doi.org/10.1038/nmeth.1903
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nmeth.1903
This article is cited by
-
Optimized workflow to modify microRNA expression in primary human intravascular cells
BMC Immunology (2023)
-
rAAV-based and intraprostatically delivered miR-34a therapeutics for efficient inhibition of prostate cancer progression
Gene Therapy (2022)
-
Learning noncoding RNA biology from viruses
Mammalian Genome (2022)
-
Small RNAs in eucaryotes: new clues for amplifying microRNA benefits
Cell & Bioscience (2020)
-
Nuclear miR-665 aggravates heart failure via suppressing phosphatase and tensin homolog transcription
Science China Life Sciences (2020)